HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark H H Kramer Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2022Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
1/2022Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
1/2022Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
1/2022Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
1/2021Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
12/2020SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
11/2020Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
10/2020Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
1/2020The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
1/2020Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark H H Kramer Research Topics

Disease

36Type 2 Diabetes Mellitus (MODY)
01/2022 - 01/2010
16Overweight
01/2022 - 12/2014
7Body Weight (Weight, Body)
01/2022 - 04/2016
3Pneumonia (Pneumonitis)
08/2022 - 12/2006
3Weight Loss (Weight Reduction)
01/2022 - 01/2016
3Obesity
01/2022 - 01/2022
3Insulin Resistance
01/2020 - 01/2010
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2017 - 08/2015
2Neoplasms (Cancer)
08/2022 - 08/2003
2Fever (Fevers)
08/2022 - 04/2007
2Infections
08/2022 - 04/2017
2Hypotension (Low Blood Pressure)
01/2021 - 10/2020
2Hyperglycemia
01/2020 - 04/2017
2Delirium
01/2018 - 08/2014
2Hypoglycemia (Reactive Hypoglycemia)
10/2017 - 08/2015
2Diabetic Nephropathies (Diabetic Nephropathy)
10/2017 - 05/2015
2Cardiovascular Diseases (Cardiovascular Disease)
04/2017 - 02/2009
2Head and Neck Neoplasms (Head and Neck Cancer)
01/2016 - 10/2013
2Protein C Deficiency
09/2007 - 07/2003
2Venous Thromboembolism
06/2007 - 02/2007
2Pulmonary Embolism
02/2007 - 01/2006
2Thrombosis (Thrombus)
07/2003 - 12/2002
2Venous Thrombosis (Deep-Vein Thrombosis)
07/2003 - 12/2002
1Fever of Unknown Origin
08/2022
1Neutropenia
08/2022
1Febrile Neutropenia
08/2022
1Respiratory Insufficiency (Respiratory Failure)
08/2022
1Septic Shock (Toxic Shock Syndrome)
08/2022
1COVID-19
01/2022
1Lymphadenopathy
01/2021
1Sarcoidosis (Schaumann Disease)
01/2021
1Granuloma
01/2021
1Ketosis
12/2020

Drug/Important Bio-Agent (IBA)

17Glucose (Dextrose)FDA LinkGeneric
01/2022 - 01/2010
10Exenatide (Byetta)FDA Link
01/2022 - 06/2015
10Metformin (Glucophage)FDA LinkGeneric
01/2022 - 12/2016
8Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022 - 09/2013
8LiraglutideFDA Link
01/2021 - 11/2016
8Glucagon-Like Peptide-1 ReceptorIBA
03/2019 - 06/2015
7Sitagliptin Phosphate (Januvia)FDA Link
01/2021 - 11/2016
7Glucagon-Like Peptide 1 (GLP 1)IBA
01/2019 - 01/2010
6dapagliflozinIBA
01/2022 - 01/2020
6Insulin (Novolin)FDA Link
01/2020 - 01/2010
5Pharmaceutical PreparationsIBA
08/2022 - 08/2014
5AnticoagulantsIBA
06/2007 - 07/2003
4Dipeptidyl-Peptidase IV InhibitorsIBA
11/2020 - 10/2016
4Insulin Glargine (Lantus)FDA Link
01/2019 - 01/2017
4insulin glulisineFDA Link
01/2019 - 12/2017
4lixisenatideIBA
01/2019 - 12/2017
3Anti-Bacterial Agents (Antibiotics)IBA
08/2022 - 12/2006
3SodiumIBA
01/2022 - 11/2019
3LinagliptinIBA
01/2022 - 10/2020
3glimepiride (Amarel)FDA LinkGeneric
01/2022 - 10/2020
3Sodium-Glucose Transport ProteinsIBA
12/2020 - 04/2017
3Gliclazide (Diamicron)IBA
12/2020 - 01/2020
3Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
11/2020 - 04/2016
3IncretinsIBA
10/2017 - 11/2015
3Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
12/2016 - 11/2015
3Glucagon-Like Peptides (Enteroglucagon)IBA
12/2016 - 11/2015
2Sodium-Glucose Transporter 2 InhibitorsIBA
12/2020 - 01/2020
2InulinFDA Link
01/2020 - 01/2020
2Glucagon-Like Peptide ReceptorsIBA
11/2019 - 12/2017
2Hypoglycemic Agents (Hypoglycemics)IBA
11/2019 - 08/2015
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2019 - 10/2016
2Haloperidol (Haldol)FDA LinkGeneric
01/2018 - 08/2014
2CreatinineIBA
12/2017 - 11/2016
2AlbuminsIBA
12/2017 - 11/2016
2EnzymesIBA
03/2017 - 04/2016
2PlacebosIBA
12/2016 - 11/2016
2GoldIBA
11/2016 - 08/2015
2Prothrombin (Factor II)IBA
09/2007 - 07/2003
2fibrin fragment D (D-dimer)IBA
01/2006 - 12/2002
1Carbapenems (Carbapenem Antibiotics)IBA
08/2022
1Meropenem (Merrem)FDA LinkGeneric
08/2022
1Imipenem Drug Combination Cilastatin (Primaxin)FDA Link
08/2022
1Antihypertensive Agents (Antihypertensives)IBA
01/2021
1Polyurethanes (Polyurethane)IBA
01/2021
1Polyethylene Terephthalates (Polyethylene Terephthalate)IBA
01/2021
1SiliconesIBA
01/2021
1Chenodeoxycholic Acid (Chenix)FDA Link
01/2021
1Cholic AcidIBA
01/2021
1Bile Acids and Salts (Bile Acids)IBA
01/2021
1Ursodeoxycholic Acid (Urso)FDA LinkGeneric
01/2021
1Deoxycholic Acid (Sodium Deoxycholate)IBA
01/2021
1ElectrolytesIBA
12/2020
1boldenone undecylenate (Equipoise)IBA
12/2020
1MagnesiumIBA
12/2020
1AcidsIBA
12/2020
1Phosphates (Orthophosphate)IBA
12/2020
1p-Aminohippuric Acid (p-Aminohippurate)FDA Link
01/2020

Therapy/Procedure

11Therapeutics
01/2022 - 02/2007
3Drug Therapy (Chemotherapy)
08/2022 - 08/2003
3Glycemic Control
12/2020 - 08/2015
3Length of Stay
01/2019 - 12/2006
2Radiotherapy
01/2016 - 10/2013
2Activities of Daily Living (ADL)
08/2014 - 12/2013
1Stem Cell Transplantation
08/2022
1Patient Transfer (Patient Dumping)
01/2022
1Lasers (Laser)
01/2021
1Breast Implants (Breast Implant)
01/2021